Original release date: April 28, 2020
Access to this course expires on: February 16, 2023 at 11:59 PM Pacific Time
Faculty: Robert A. Anders, MD, PhD
- Understand the value of the tumor immune microenvironment in cancer patient prognosis
- Discuss the use of microsatellite unstable (MSI HI) / mismatch repair deficiency testing in relation to immune based anti-cancer therapy.
- Gain knowledge of how newer immune based anti-cancer therapies will likely impact diagnostic pathology
- Explain the challenges in reporting PD-L1 immunohistochemical staining